PEG-Free Polyion Complex Nanocarriers for Brain Derived Neurotrophic Factor

Abstract

Many therapeutic formulations incorporate poly(ethylene glycol) (PEG) as a stealth component to minimize early clearance. However, PEG is immunogenic and susceptible to accelerated clearance after multiple administrations. Here, we present two novel reformulations of a polyion complex (PIC), originally comprised of poly(ethylene glycol)₁₁₃-b-poly(glutamic acid)₅₀ (PEG-PLE) and brain derived neurotrophic factor (BDNF), termed Nano-BDNF (Nano-BDNF PEG-PLE). We replace the PEG based block copolymer with two new polymers, poly(sarcosine)₁₂₇ -b-poly(glutamic acid)₅₀ (PSR-PLE) and poly(methyl-2-oxazolines)₃₈ -b-poly(oxazolepropanoic acid)₂₇ -b-(poly(methyl-2-oxazoline)₃₈ (PMeOx-PPaOx-PMeOx) which are driven to association with BDNF via electrostatic interactions and hydrogen bonding to form a PIC. Formulation using a microfluidic mixer yields small and narrowly disperse nanoparticles which associate following similar principles. Additionally, we demonstrate that encapsulation does not inhibit access by the receptor kinase, which effects BDNF's physiologic benefits. Finally, we investigate the formation of nascent nanoparticles through a series of characterization experiments and isothermal titration experiments which show the effects of pH in the context of particle self-assembly. Our findings indicate that thoughtful reformulation of PEG based, therapeutic PICs with non-PEG alternatives can be accomplished without compromising the self-assembly of the PIC.

Competing Interest Statement

AVK is an inventor on pending patents (e.g., US Pat Application 20190111109). No other authors have any conflicts to report.